Half of all drugs that received accelerated approval by the FDA from 2009-2013 failed to complete required post-approval studies within three years of going on the market, according to a study published Tuesday in JAMA. Another study, also in JAMA, found that less than half of all high-risk medical device modifications underwent rigorous testing before entering the market.

Since 1992, drugs that treat serious illnesses have had the option of fast-tracking their FDA approval. Instead of completing rigorous clinical trials that can take years, the FDA would allow companies to put promising drugs on the market on the condition that they continue to conduct studies that prove that the drugs actually work.

What they did: The first study looked at 38 trials for 22 drugs, and found that only 19 of those trials were completed within three years. The ones that were finished were frequently not as rigorous as the studies that would have been required had the drug been approved via normal channels. There was also evidence of missing or lost data and selection bias.

It's not all bad, notes STAT's Damien Garde, who writes that a study published this week in Health Affairs concludes "that the agency is consistently singling out the most promising therapies [for] speedy review."

Go deeper

Trump tightens screws on ByteDance to sell Tiktok

Illustration: Aïda Amer/Axios

President Trump added more pressure Friday night on China-based TikTok parent ByteDance to exit the U.S., ordering it to divest all assets related to the U.S. operation of TikTok within 90 days.

Between the lines: The order means ByteDance must be wholly disentangled from TikTok in the U.S. by November. Trump had previously ordered TikTok banned if ByteDance hadn't struck a deal within 45 days. The new order likely means ByteDance has just another 45 days after that to fully close the deal, one White House source told Axios.

Updated 9 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 9:30 p.m. ET: 21,056,850 — Total deaths: 762,293— Total recoveries: 13,100,902Map.
  2. U.S.: Total confirmed cases as of 9:30 p.m ET: 5,306,215 — Total deaths: 168,334 — Total recoveries: 1,796,309 — Total tests: 65,676,624Map.
  3. Health: CDC: Survivors of COVID-19 have up to three months of immunity Fauci believes normalcy will return by "the end of 2021" with vaccine — The pandemic's toll on mental health — FDA releases first-ever list of medical supplies in shortage.
  4. States: California passes 600,000 confirmed coronavirus cases.
  5. Cities: Coronavirus pandemic dims NYC's annual 9/11 Tribute in Light.
  6. Business: How small businesses got stiffed — Unemployment starts moving in the right direction.
  7. Politics: Biden signals fall strategy with new ads.

Harris: "Women are going to be a priority" in Biden administration

Sen. Kamala Harris at an event in Wilmington, Del. Photo: Drew Angerer/Getty Images

In her first sit-down interview since being named Joe Biden's running mate, Sen. Kamala Harris talked about what she'll do to fight for women if elected VP, and how the Democrats are thinking about voter turnout strategies ahead of November.

What they're saying: "In a Biden-Harris administration women are going to be a priority, understanding that women have many priorities and all of them must be acknowledged," Harris told The 19th*'s Errin Haines-Whack.